Can administering Rituximab still be clinically effective even if there is evidence of depletion of CD19 B cells on flow cytometry?   

The main driver of this question is that there is some evidence that Rituximab may have modulating effects on B cells in lymphoid tissue that we do not have any clinically useful assays to measure counts/functionality.